Dyne Therapeutics’ (DYN) “Buy” Rating Reiterated at Chardan Capital

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $50.00 price target on the stock. Chardan Capital’s target price would suggest a potential upside of 64.96% from the company’s previous close.

Other research analysts have also issued research reports about the company. Guggenheim boosted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday. Stifel Nicolaus lifted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Oppenheimer reissued an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Stock Performance

DYN stock opened at $30.31 on Wednesday. Dyne Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $47.45. The firm has a fifty day moving average price of $32.58 and a 200 day moving average price of $35.08. The firm has a market cap of $3.04 billion, a PE ratio of -8.51 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, equities analysts predict that Dyne Therapeutics will post -2.99 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox purchased 32,000 shares of the stock in a transaction on Wednesday, September 4th. The shares were bought at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the transaction, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. This trade represents a -133.33 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Dirk Kersten sold 23,671 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the transaction, the director now owns 99,652 shares in the company, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its position in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Dyne Therapeutics during the 3rd quarter valued at about $34,000. US Bancorp DE raised its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $62,000. Finally, KBC Group NV boosted its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.